China Life Sciences Newsletter -- April 2012


In This Issue:

*Investor Q&A

*Trends and Best Practices in R&D Strategic Partnerships in China

*USPTO Proposed Rules on Preissuance Submissions

Excerpt from Investor Q&A

Interview by Chuck Comey, Dave Chang, and Patrick Fischer

John Oyler is the founder and CEO of BeiGene Ltd., a Beijing-based biotechnology company that focuses on discovering and developing innovative oncology drugs. Few can match Mr. Oyler’s record as a serial founder. He previously founded and was CEO of BioDuro, a 700-person integrated contract research organization (CRO) in Beijing, which was sold to PPD with attractive returns. Mr. Oyler is also the former CEO of Galenea, a Bostonbased biotech spinout from Massachusetts Institute of Technology with funding from Otsuka; the former co-CEO of Genta, a publicly traded oncology company that grew to be worth $1.7 billion; and the former founder and president of Telephia, which was bought by Nielsen. He holds an MBA from Stanford University and a BS from Massachusetts Institute of Technology.

Please see full newsletter below for more information.

LOADING PDF: If there are any problems, click here to download the file.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Morrison & Foerster LLP | Attorney Advertising

Written by:


Morrison & Foerster LLP on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:

Sign up to create your digest using LinkedIn*

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.